Free Trial

Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Price Target at $216.19

Alnylam Pharmaceuticals logo with Medical background

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seventeen ratings firms that are presently covering the stock, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $216.19.

ALNY has been the topic of a number of research reports. Cantor Fitzgerald reissued a "neutral" rating and issued a $165.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. William Blair reissued an "outperform" rating on shares of Alnylam Pharmaceuticals in a report on Monday, April 8th. HC Wainwright lifted their price objective on shares of Alnylam Pharmaceuticals from $395.00 to $400.00 and gave the stock a "buy" rating in a research note on Tuesday, May 7th. Royal Bank of Canada reissued an "outperform" rating and set a $235.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. Finally, Chardan Capital restated a "buy" rating and issued a $225.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, May 3rd.

Read Our Latest Stock Report on ALNY

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Amy W. Schulman sold 21,700 shares of the stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the completion of the sale, the director now owns 8,436 shares in the company, valued at approximately $1,253,589.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.50% of the stock is currently owned by insiders.


Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC lifted its stake in shares of Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 143 shares during the last quarter. Quent Capital LLC raised its holdings in Alnylam Pharmaceuticals by 246.0% during the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 123 shares in the last quarter. Anchor Investment Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $38,000. Altitude Crest Partners Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter worth about $30,000. Finally, GAMMA Investing LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $52,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY traded down $3.44 during midday trading on Wednesday, reaching $153.86. 587,748 shares of the company traded hands, compared to its average volume of 600,422. The stock has a 50-day moving average price of $150.04 and a 200 day moving average price of $162.50. The company has a market cap of $19.46 billion, a price-to-earnings ratio of -57.41 and a beta of 0.30. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.23. The company had revenue of $494.33 million for the quarter, compared to the consensus estimate of $428.01 million. During the same quarter last year, the firm posted ($1.40) earnings per share. The firm's quarterly revenue was up 54.8% compared to the same quarter last year. As a group, analysts expect that Alnylam Pharmaceuticals will post -3.77 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

(Get Free Report

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Featured Articles

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

→ $5k to $1.3m in just 3 trades (From Insiders Exposed) (Ad)

Should you invest $1,000 in Alnylam Pharmaceuticals right now?

Before you consider Alnylam Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.

While Alnylam Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Roaring Kitty's GameStop Gamble: What Went Wrong?

Roaring Kitty's GameStop Gamble: What Went Wrong?

Keith Gill, aka Roaring Kitty, turned a modest investment into a massive payday with GameStop. But there's more to the story.

Related Videos

GameStop Mania: Which Meme Stocks Will Follow?
Profit Like Congress: The Stocks They’re Betting On
Home Depot: Earnings Mixed, Wait to Buy the Dip

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines